{
  "ticker": "EMR",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02967906",
  "id": "02967906",
  "pages": 8,
  "price_sensitive": false,
  "date": "20250709",
  "time": "1825",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250709/pdf/06ln7fbyryvxlm.pdf",
  "summary": "### Key Points:  \n- **Options Exercised**: Conversion of options into **1,275,000 new ordinary shares (EMR)**.  \n  - **175,000 shares** issued at **A$1.09** (from EMRAK options expiring 29-Jul-2026).  \n  - **1,100,000 shares** issued at **A$0.67** (from EMRAE options expiring 30-Jul-2025), including **1,000,000 by KMP Michael Evans**.  \n- **Post-Issue Capital**:  \n  - Total ordinary shares on issue: **658,865,123**.  \n  - Unquoted options: **13,825,500** across multiple tranches (details in announcement).  \n\n**No material valuation or liquidity impacts identified (routine option conversions).**",
  "usage": {
    "prompt_tokens": 2743,
    "completion_tokens": 177,
    "total_tokens": 2920,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-09T08:58:55.774568"
}